Takehiro Okumura

May 14, 2024 | laboratorynetwork.com | PANKAJ SINGH |Takehiro Okumura |Zeb Khan

By Pankaj Singh, Global Market InsightsYou can't improve what you don't measure. This discussion explores advances in cell counting technology and the growing number of ways it aids the biotech industry and beyond. By Takehiro Okumura and Zeb Khan, Takeda PharmaceuticalsWould you ever need to follow GMP standards in workspaces where GMP is not required or possible? This article digs into why, when, and how to follow the principles of GMP.

May 8, 2024 | advancingrna.com | AR Welch |Advancing RNA |Takehiro Okumura |Zeb Khan

Designing a Plasmid DNA Downstream Purification ProcessDiscover in our technical article the Downstream Purification in the Plasmid DNA (pDNA) Manufacturing Process. Plasmid DNA (pDNA) is an essential component of, and key technology for production of viral vector, mRNA, and vaccine therapies.

May 3, 2024 | cellandgene.com | Zeb Khan |Takehiro Okumura |Erich Bozenhardt |Rajendran Arunagiri

Hello Cell & Gene readers,I'm happy to bring you April's most-clicked articles. Enjoy!Erin Harris, editor in chief Follow me on XAPRIL'S BEST FEATURED EDITORIALWhen Does GMP Matter In Non-GMP Settings? Would you ever need to follow GMP standards in workspaces where GMP is not required or possible? This article digs into why, when, and how to follow the principles of GMP.

Apr 5, 2024 | advancingrna.com | Takehiro Okumura |Zeb Khan

Guest Column | April 5, 2024 By Takehiro Okumura and Zeb Khan, Takeda Pharmaceuticals Regulatory agencies allow for manufacturing materials such as genome editing materials, the generation of iPS cells, and the subsequent selection process under principles of GMP or GMP-like operation instead of full GMP compliance.1,2,3,4 In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) does not specify whether to use GMP or non-GMP during the clinical phase and the clinical study sponsor owns...

Apr 5, 2024 | cellandgene.com | Takehiro Okumura |Zeb Khan

Guest Column | April 5, 2024 By Takehiro Okumura and Zeb Khan, Takeda Pharmaceuticals Regulatory agencies allow for manufacturing materials such as genome editing materials, the generation of iPS cells, and the subsequent selection process under principles of GMP or GMP-like operation instead of full GMP compliance.1,2,3,4 In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) does not specify whether to use GMP or non-GMP during the clinical phase and the clinical study sponsor owns...